Alexion

Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating conditions. The company is involved in biotechnology research and offers therapies that treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among others, enabling individuals to overcome the issues they face every day.

Partnerships

 

  

  

 

  

  

 

  

  

Clients